{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:28:09Z","timestamp":1791217689965,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40265-013-0105-4","type":"journal-article","created":{"date-parts":[[2013,8,5]],"date-time":"2013-08-05T07:45:02Z","timestamp":1375688702000},"page":"1405-1415","source":"Crossref","is-referenced-by-count":137,"title":["Non-dopaminergic Treatments for Motor Control in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"73","author":[{"given":"Susan H.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"105_CR1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410270405","volume":"27","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson\u2019s disease. Ann Neurol. 1990;27:373\u201385.","journal-title":"Ann Neurol"},{"key":"105_CR2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","volume":"60","author":"C Zarow","year":"2003","unstructured":"Zarow C, Lyness SA, Mortimer JA, et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337\u201341.","journal-title":"Arch Neurol"},{"key":"105_CR3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"105_CR4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumbergs PC, Cotton RG, et al. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson\u2019s disease. Brain Res. 1990;510(1):104\u20137.","journal-title":"Brain Res"},{"key":"105_CR5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","volume":"50","author":"W Paulus","year":"1991","unstructured":"Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson\u2019s disease. J Neuropathol Exp Neurol. 1991;50:743\u201355.","journal-title":"J Neuropathol Exp Neurol"},{"key":"105_CR6","first-page":"120","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain. 2008;131:120\u201331.","journal-title":"Brain"},{"key":"105_CR7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/ana.20102","volume":"55","author":"AE Lang","year":"2004","unstructured":"Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson\u2019s disease. Ann Neurol. 2004;55:761\u20135.","journal-title":"Ann Neurol"},{"key":"105_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot P, Johnston TH, Koprich JB, et al. The pharmacology of l-DOPA-induced dyskinesia in Parkinson\u2019s disease. Pharmacol Rev. 2013;65:1\u201352.","journal-title":"Pharmacol Rev"},{"key":"105_CR9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577\u201388.","journal-title":"Nat Rev Neurosci"},{"key":"105_CR10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","volume":"20","author":"JM Brotchie","year":"2005","unstructured":"Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord. 2005;20:919\u201331.","journal-title":"Mov Disord"},{"key":"105_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/nmt.11.62","volume":"6","author":"P Huot","year":"2011","unstructured":"Huot P, Fox SH. Nondopaminergic treatments for Parkinson\u2019s disease. Neurodegener Dis Manag. 2011;6:491\u2013512.","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"105_CR12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mds.25273","volume":"28","author":"L Kalia","year":"2013","unstructured":"Kalia L, Brotchie JM, Fox SH. Non dopaminergic therapies for PD motor symptoms; update on recent clinical trials. Mov Disord. 2013;28(2):131\u201344.","journal-title":"Mov Disord"},{"key":"105_CR13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","volume":"16","author":"B Gomez-Mancilla","year":"1993","unstructured":"Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on l-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol. 1993;16:418\u201327.","journal-title":"Clin Neuropharmacol"},{"key":"105_CR14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","volume":"7","author":"SH Fox","year":"2008","unstructured":"Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson\u2019s disease. Lancet Neurol. 2008;7:927\u201338.","journal-title":"Lancet Neurol"},{"key":"105_CR15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","volume":"29","author":"MA Schwarzschild","year":"2006","unstructured":"Schwarzschild MA, Agnati L, Fuxe K, et al. Targeting adenosine A2A receptors in Parkinson\u2019s disease. Trends Neurosci. 2006;29:647\u201354.","journal-title":"Trends Neurosci"},{"key":"105_CR16","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","volume":"20","author":"JE Nash","year":"2000","unstructured":"Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson\u2019s disease. J Neurosci. 2000;20:7782\u20139.","journal-title":"J Neurosci"},{"key":"105_CR17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","volume":"43","author":"T Kanda","year":"1998","unstructured":"Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43:507\u201313.","journal-title":"Ann Neurol"},{"key":"105_CR18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","volume":"16","author":"HH Fernandez","year":"2010","unstructured":"Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord. 2010;16:16\u201320.","journal-title":"Parkinsonism Relat Disord"},{"key":"105_CR19","unstructured":"Merck. A phase 3, double-blind, double-dummy, placebo- and active-controlled dose-range-finding efficacy and safety study of preladenant in subjects with early Parkinson\u2019s disease. ClinicalTrials.gov (Internet). Bethesda: National Library of Medicine (US); 2000. http:\/\/clinicaltrials.gov\/show\/NCT01155479 . Cited 13 May 2013."},{"issue":"1","key":"105_CR20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mds.23954","volume":"27","author":"F Stocchi","year":"2012","unstructured":"Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson\u2019s disease patients. Mov Disord. 2012;27(1):106\u201312.","journal-title":"Mov Disord"},{"key":"105_CR21","doi-asserted-by":"crossref","unstructured":"Barone P, Fernandez H, Ferreira J, et al. Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). In: Abstract 65th Annual American Academy of Neurology poster 1.061; 2013.","DOI":"10.1212\/WNL.80.7_supplement.P01.061"},{"key":"105_CR22","doi-asserted-by":"crossref","unstructured":"Schapira AH, Fox S, Hauser R, et al., on behalf of the SETTLE Investigators. Safinamide add on to l-dopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkinson\u2019s disease (PD) and motor fluctuations (SETTLE). In: Abstract 65th Annual American Academy of Neurology poster 1.062; 2013.","DOI":"10.1212\/WNL.80.7_supplement.P01.062"},{"key":"105_CR23","doi-asserted-by":"crossref","unstructured":"Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68(1):45\u201350.","DOI":"10.1212\/01.wnl.0000250236.75053.16"},{"issue":"3","key":"105_CR24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","volume":"61","author":"W Bara-Jimenez","year":"2003","unstructured":"Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson\u2019s disease. Neurology. 2003;61(3):293\u20136.","journal-title":"Neurology"},{"issue":"3","key":"105_CR25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","volume":"61","author":"RA Hauser","year":"2003","unstructured":"Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61(3):297\u2013303.","journal-title":"Neurology"},{"issue":"23","key":"105_CR26","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","volume":"70","author":"M Stacy","year":"2008","unstructured":"Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233\u201340.","journal-title":"Neurology"},{"issue":"3","key":"105_CR27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","volume":"63","author":"PA LeWitt","year":"2008","unstructured":"LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295\u2013302.","journal-title":"Ann Neurol"},{"issue":"10","key":"105_CR28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","volume":"25","author":"Y Mizuno","year":"2010","unstructured":"Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: a randomized, controlled study. Mov Disord. 2010;25(10):1437\u201343.","journal-title":"Mov Disord"},{"issue":"15","key":"105_CR29","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/mds.22095","volume":"23","author":"RA Hauser","year":"2008","unstructured":"Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson\u2019s disease on levodopa with motor fluctuations. Mov Disord. 2008;23(15):2177\u201385.","journal-title":"Mov Disord"},{"key":"105_CR30","doi-asserted-by":"crossref","unstructured":"Mizuno Y, Kondo T, the Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily off time in Parkinson\u2019s disease. Mov Disord. 2013. doi: 10.1002\/mds.25418 .","DOI":"10.1002\/mds.25418"},{"issue":"3","key":"105_CR31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","volume":"10","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10(3):221\u20139.","journal-title":"Lancet Neurol"},{"key":"105_CR32","unstructured":"Merck. A phase 3, 12-week, double-blind, double-dummy, placebo- and active-controlled efficacy and safety study of preladenant in subjects with moderate to severe Parkinson\u2019s disease. ClinicalTrials.gov (Internet). Bethesda: National Library of Medicine (US); 2000. http:\/\/clinicaltrials.gov\/show\/NCT01155466 . Cited 13 May 2013."},{"key":"105_CR33","unstructured":"Biotie. A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson\u2019s subjects with end of dose wearing off. ClinicalTrials.gov (Internet). Bethesda: National Library of Medicine (US); 2000. http:\/\/clinicaltrials.gov\/show\/NCT01283594 . Cited 23 May 2013."},{"key":"105_CR34","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","volume":"21","author":"SH Fox","year":"2006","unstructured":"Fox SH, Lang AE, Brotchie JM. Translation of non-dopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord. 2006;21:1578\u201394.","journal-title":"Mov Disord"},{"key":"105_CR35","first-page":"60","volume":"47","author":"P Calabresi","year":"2000","unstructured":"Calabresi P, Giacomini P, Centonze D, et al. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol. 2000;47:60\u20138.","journal-title":"Ann Neurol"},{"issue":"10","key":"105_CR36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","volume":"6","author":"PJ Conn","year":"2005","unstructured":"Conn PJ, Battaglia G, Marino MJ, et al. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005;6(10):787\u201398.","journal-title":"Nat Rev Neurosci"},{"issue":"12","key":"105_CR37","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","volume":"26","author":"S Duty","year":"2012","unstructured":"Duty S. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson\u2019s disease. CNS Drugs. 2012;26(12):1017\u201332.","journal-title":"CNS Drugs"},{"issue":"Suppl 3","key":"105_CR38","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","volume":"26","author":"SH Fox","year":"2011","unstructured":"Fox SH, Katzenschlager R, Lim SY, et al. Movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2011;26(Suppl 3):S2\u201341.","journal-title":"Mov Disord"},{"key":"105_CR39","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","volume":"25","author":"E Wolf","year":"2010","unstructured":"Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease. Mov Disord. 2010;25:1357\u201363.","journal-title":"Mov Disord"},{"key":"105_CR40","unstructured":"Adamas Pharmaceuticals, Inc. Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study). ClinicalTrials.gov (Internet). Bethesda: National Library of Medicine (US); 2000. http:\/\/clinicaltrials.gov\/show\/NCT01397422 . Cited 9 May 2013."},{"key":"105_CR41","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/archneur.58.10.1660","volume":"58","author":"Parkinson Study Group","year":"2001","unstructured":"Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol. 2001;58:1660\u20138.","journal-title":"Arch Neurol"},{"issue":"2","key":"105_CR42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mds.23983","volume":"27","author":"A Lees","year":"2012","unstructured":"Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing \u201coff\u201d time in Parkinson\u2019s disease. Mov Disord. 2012;27(2):284\u20138.","journal-title":"Mov Disord"},{"issue":"7","key":"105_CR43","first-page":"720","volume":"5","author":"TH Johnston","year":"2004","unstructured":"Johnston TH, Brotchie JM. Drugs in development for Parkinson\u2019s disease. Curr Opin Investig Drugs. 2004;5(7):720\u20136.","journal-title":"Curr Opin Investig Drugs"},{"key":"105_CR44","unstructured":"Rascol O, Fox SH, Gasparini F, et al. Use of metabotropic glutamate 5 receptor antagonists for treatment of levodopa-induced dyskinesias. Mov Disord (in press)."},{"issue":"7","key":"105_CR45","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","volume":"26","author":"D Berg","year":"2011","unstructured":"Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord. 2011;26(7):1243\u201350.","journal-title":"Mov Disord"},{"key":"105_CR46","doi-asserted-by":"crossref","unstructured":"Tison F, Durif F, Ferrand C, et al. Safety, tolerability and anti-dyskinetic efficacy of dipraglurant, a novel mGluR5 negative allosteric modulator (NAM) in Parkinson\u2019s disease (PD) patients with levodopa-induced dyskinesia (LID). In: Abstract 65th Annual American Academy of Neurology poster 23.004; Mar 2013.","DOI":"10.1212\/WNL.80.7_supplement.S23.004"},{"issue":"2\u20133","key":"105_CR47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0306-4522(91)90345-O","volume":"41","author":"M Mavridis","year":"1991","unstructured":"Mavridis M, Degryse AD, Lategan AJ, et al. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson\u2019s disease. Neuroscience. 1991;41(2\u20133):507\u201323.","journal-title":"Neuroscience"},{"issue":"12","key":"105_CR48","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00702-011-0698-2","volume":"118","author":"MM Iravani","year":"2011","unstructured":"Iravani MM, Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm. 2011;118(12):1661\u201390.","journal-title":"J Neural Transm"},{"key":"105_CR49","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","volume":"14","author":"B Henry","year":"1999","unstructured":"Henry B, Fox SH, Peggs D, et al. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of l-dopa in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord. 1999;14:744\u201353.","journal-title":"Mov Disord"},{"issue":"3","key":"105_CR50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pbb.2011.09.009","volume":"100","author":"CJ Barnum","year":"2012","unstructured":"Barnum CJ, Bhide N, Lindenbach D, et al. Effects of noradrenergic denervation on l-DOPA-induced dyskinesia and its treatment by \u03b1- and \u03b2-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol Biochem Behav. 2012;100(3):607\u201315.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"105_CR51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","volume":"79","author":"PA Lewitt","year":"2012","unstructured":"Lewitt PA, Hauser RA, Lu M, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology. 2012;79(2):163\u20139.","journal-title":"Neurology"},{"key":"105_CR52","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130:1819\u201333.","journal-title":"Brain"},{"key":"105_CR53","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","volume":"131","author":"A Munoz","year":"2008","unstructured":"Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain. 2008;131:3380\u201394.","journal-title":"Brain"},{"key":"105_CR54","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jnnp.54.4.376-a","volume":"54","author":"B Kleedorfer","year":"1991","unstructured":"Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry. 1991;54:376\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"105_CR55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22:179\u201386.","journal-title":"Mov Disord"},{"key":"105_CR56","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson\u2019s disease. Mov Disord. 2008;23:700\u20137.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"105_CR57","first-page":"S277","volume":"24","author":"JJ Sage","year":"2009","unstructured":"Sage JJ, Hauser RA, Cordon ME, Gonzalez MA, Tani Y, Koyamam M, Apfel SC, Reed RF, Okamato M, Gertbner JM. Pilot study of the efficacy and safety of piclozotan in Parkinson\u2019s disease patients with l-dopa induced motor complications. Mov Disord. 2009;24(Suppl 1):S277.","journal-title":"Mov Disord"},{"issue":"4","key":"105_CR58","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.parkreldis.2011.12.006","volume":"18","author":"O Rascol","year":"2012","unstructured":"Rascol O, Bronzova J, Hauser RA, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson\u2019s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord. 2012;18(4):370\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"105_CR59","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158(3):360\u20139.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"105_CR60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004;62(3):381\u20138.","journal-title":"Neurology"},{"issue":"2","key":"105_CR61","first-page":"295","volume":"75","author":"R Katzenschlager","year":"2004","unstructured":"Katzenschlager R, Manson AJ, Evans A, et al. Low dose quetiapine for drug induced dyskinesias in Parkinson\u2019s disease: a double blind cross over study. J Neurol Neurosurg Psychiatry. 2004;75(2):295\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"105_CR62","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/mds.10542","volume":"18","author":"MP Hill","year":"2003","unstructured":"Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by l-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord. 2003;18(11):1301\u20135.","journal-title":"Mov Disord"},{"issue":"1\u20133","key":"105_CR63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","volume":"485","author":"E Bezard","year":"2004","unstructured":"Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol. 2004;485(1\u20133):159\u201364.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"105_CR64","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","volume":"310","author":"MP Hill","year":"2004","unstructured":"Hill MP, Ravenscroft P, Bezard E, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson\u2019s disease. J Pharmacol Exp Ther. 2004;310(1):386\u201394.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"105_CR65","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00702-010-0472-x","volume":"117","author":"M Wolz","year":"2010","unstructured":"Wolz M, L\u00f6hle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm. 2010;117(11):1279\u201386.","journal-title":"J Neural Transm"},{"issue":"2","key":"105_CR66","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/mds.23355","volume":"26","author":"P Stathis","year":"2011","unstructured":"Stathis P, Konitsiotis S, Tagaris G, et al. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord. 2011;26(2):264\u201370.","journal-title":"Mov Disord"},{"issue":"8","key":"105_CR67","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/mds.23687","volume":"26","author":"KK Wong","year":"2011","unstructured":"Wong KK, Alty JE, Goy AG, et al. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson\u2019s disease. Mov Disord. 2011;26(8):1552\u20135.","journal-title":"Mov Disord"},{"issue":"3","key":"105_CR68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/01.WNF.0000220814.48360.F4","volume":"29","author":"KE Lyons","year":"2006","unstructured":"Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol. 2006;29(3):148\u201353.","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"105_CR69","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.20563","volume":"20","author":"TA Zesiewicz","year":"2005","unstructured":"Zesiewicz TA, Sullivan KL, Maldonado JL, et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord. 2005;20(9):1205\u20139.","journal-title":"Mov Disord"},{"issue":"6","key":"105_CR70","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20\u00a0years. Mov Disord. 2008;23(6):837\u201344.","journal-title":"Mov Disord"},{"key":"105_CR71","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0031-9384(02)00935-6","volume":"77","author":"CD Balaban","year":"2002","unstructured":"Balaban CD. Neural substrates linking balance control and anxiety. Physiol Behav. 2002;77:469\u201375.","journal-title":"Physiol Behav"},{"key":"105_CR72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02260912","volume":"5","author":"H Tohgi","year":"1993","unstructured":"Tohgi H, Abe T, Takahashi S. The effects of l-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect. 1993;5:27\u201334.","journal-title":"J Neural Transm Park Dis Dement Sect"},{"issue":"2","key":"105_CR73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mehy.2012.11.031","volume":"80","author":"K Fukada","year":"2013","unstructured":"Fukada K, Endo T, Yokoe M, et al. l-Threo-3,4-dihydroxyphenylserine (l-DOPS) co-administered with entacapone improves freezing of gait in Parkinson\u2019s disease. Med Hypotheses. 2013;80(2):209\u201312.","journal-title":"Med Hypotheses"},{"key":"105_CR74","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1124\/jpet.106.110015","volume":"319","author":"DM Devilbiss","year":"2006","unstructured":"Devilbiss DM, Berridge CW. Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge. J Pharmacol Exp Ther. 2006;319:1327\u201335.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"105_CR75","doi-asserted-by":"crossref","first-page":"RC121","DOI":"10.1523\/JNEUROSCI.21-02-j0001.2001","volume":"21","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121.","journal-title":"J Neurosci"},{"issue":"14","key":"105_CR76","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.0b013e3182143537","volume":"76","author":"AJ Espay","year":"2011","unstructured":"Espay AJ, Dwivedi AK, Payne M, et al. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology. 2011;76(14):1256\u201362.","journal-title":"Neurology"},{"issue":"7","key":"105_CR77","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(12)70106-0","volume":"11","author":"C Moreau","year":"2012","unstructured":"Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson\u2019s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11(7):589\u201396.","journal-title":"Lancet Neurol"},{"issue":"20","key":"105_CR78","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1212\/WNL.0b013e3181c1ded6","volume":"73","author":"NI Bohnen","year":"2009","unstructured":"Bohnen NI, M\u00fcller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73(20):1670\u20136.","journal-title":"Neurology"},{"issue":"8","key":"105_CR79","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1172\/JCI42642","volume":"120","author":"C Karachi","year":"2010","unstructured":"Karachi C, Grabli D, Bernard FA, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Investig. 2010;120(8):2745\u201354.","journal-title":"J Clin Investig"},{"key":"105_CR80","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","volume":"75","author":"KA Chung","year":"2010","unstructured":"Chung KA, Lobb BM, Nutt JG, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010;75:1263\u20139.","journal-title":"Neurology"},{"key":"105_CR81","unstructured":"Hall D, et al. Varenicline for the treatment of postural and gait dysfunction in Parkinson disease. ClinicalTrials.gov (Internet). Bethesda: National Library of Medicine (US); 2000. http:\/\/clinicaltrials.gov\/show\/NCT01341080 . Cited 14 May 2013."},{"issue":"7","key":"105_CR82","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","volume":"13","author":"MR DeLong","year":"1990","unstructured":"DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281\u20135.","journal-title":"Trends Neurosci"},{"issue":"4","key":"105_CR83","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/mds.10125","volume":"17","author":"M Ghaemi","year":"2002","unstructured":"Ghaemi M, Raethjen J, Hilker R, et al. Monosymptomatic resting tremor and Parkinson\u2019s disease: a multitracer positron emission tomographic study. Mov Disord. 2002;17(4):782\u20138.","journal-title":"Mov Disord"},{"issue":"10\u201312","key":"105_CR84","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s007020050124","volume":"105","author":"S Asenbaum","year":"1998","unstructured":"Asenbaum S, Pirker W, Angelberger P, et al. [123I]beta-CIT and SPECT in essential tremor and Parkinson\u2019s disease. J Neural Transm. 1998;105(10\u201312):1213\u201328.","journal-title":"J Neural Transm"},{"issue":"9","key":"105_CR85","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/mds.10482","volume":"18","author":"HT Benamer","year":"2003","unstructured":"Benamer HT, Oertel WH, Patterson J, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord. 2003;18(9):977\u201384.","journal-title":"Mov Disord"},{"issue":"Suppl 7","key":"105_CR86","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1002\/mds.10579","volume":"18","author":"W Pirker","year":"2003","unstructured":"Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18(Suppl 7):S43\u201351.","journal-title":"Mov Disord"},{"key":"105_CR87","first-page":"49","volume":"5","author":"LE Collins-Praino","year":"2011","unstructured":"Collins-Praino LE, Paul NE, Rychalsky KL, et al. Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor. Front Syst Neurosci. 2011;5:49.","journal-title":"Front Syst Neurosci"},{"issue":"4","key":"105_CR88","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","volume":"60","author":"M Doder","year":"2003","unstructured":"Doder M, Rabiner EA, Turjanski N, et al. Tremor in Parkinson\u2019s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 2003;60(4):601\u20135.","journal-title":"Neurology"},{"key":"105_CR89","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.0b013e318292a31d","volume":"80","author":"C Loane","year":"2013","unstructured":"Loane C, Wu K, Bain P, et al. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology. 2013;80:1850\u20135.","journal-title":"Neurology"},{"issue":"3","key":"105_CR90","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00213-002-1247-3","volume":"165","author":"BB Carlson","year":"2003","unstructured":"Carlson BB, Wisniecki A, Salamone JD. Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of parkinsonian tremor. Psychopharmacology (Berl). 2003;165(3):229\u201337.","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"105_CR91","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.48.4.1077","volume":"48","author":"JH Friedman","year":"1997","unstructured":"Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson\u2019s disease. Neurology. 1997;48(4):1077\u201381.","journal-title":"Neurology"},{"issue":"3","key":"105_CR92","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","volume":"13","author":"RM Trosch","year":"1998","unstructured":"Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson\u2019s disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord. 1998;13(3):377\u201382.","journal-title":"Mov Disord"},{"issue":"6","key":"105_CR93","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1212\/WNL.49.6.1587","volume":"49","author":"U Bonuccelli","year":"1997","unstructured":"Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson\u2019s disease tremor. Effects of acute and chronic administration. Neurology. 1997;49(6):1587\u201390.","journal-title":"Neurology"},{"issue":"2","key":"105_CR94","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1353-8020(02)00011-1","volume":"9","author":"PH Gordon","year":"2002","unstructured":"Gordon PH, Pullman SL, Louis ED, et al. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord. 2002;9(2):125\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"105_CR95","doi-asserted-by":"crossref","unstructured":"Crosby NJ, Deane KH, Clarke CE. Beta-blocker therapy for tremor in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2003;(1):CD003361.","DOI":"10.1002\/14651858.CD003361"}],"updated-by":[{"DOI":"10.1007\/s40265-014-0263-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0105-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0105-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0105-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:24:48Z","timestamp":1715808288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0105-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,6]]},"references-count":95,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0105-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,6]]}}}